The ability to metabolize the naturally occurring FXR antagonist tauro-β-muricholic acid is an essential process toward obesity, steatosis, as well as impaired tolerance to glucose and insulin. The gene discussed is INS; the disease is obesity due to melanocortin 4 receptor deficiency.